Antitrust Challenges in Pharma Distribution: A New Era
The Pharma business has historically been on the radar of the antitrust authorities. Although free competition plays crucial role in ensuring that patients receive better products at affordable prices, the industry is heavily regulated across the world. This is explained, according to the WHO, amongst other things, “by serious consequences, including injury or death, which can result from the lack or misuse of medications and by impossibility for the patient to determine product quality”. Still, freedom of market behavior should not be limited beyond what is absolutely necessary to protect the public interest and policy makers need to aim for ideal balance in this regard.
The abstract/extract view of this article is free. Access to the full text of this article requires a subscription.
Please send subscription inquiries by:
Phone: +380 44 495-27-27